WELCOME TO THE MEASURING PATIENT ENGAGEMENT SUMMIT!
With the FDA now explicitly requiring patient experience data as part of an NDA, it is more important than ever to determine how patient engagement can be quantified in a meaningful way. The implementation of standardized metrics will allow patient engagement teams to demonstrate the impact of their activities consistently and quantifiably on research programs across the breadth of stakeholders.
The Measuring Patient Engagement Summit was the definitive conference for practical answers. This event acted as the honeypot gathering for leading patient engagement experts to share their latest experiences of how they are successfully measuring patient engagement to: inform decision making in improving patient engagement, quantify the impact of patient engagement on recruitment and retention, and ensure the most meaningful outreach to patients and advocacy groups.
Bursting with real-world evidence and implementable case studies, this platform offers a unique exploration of both the hottest topics and industry bottlenecks, including:
CHARTING
a pragmatic course towards standardized metrics and reporting, drawing insights from AstraZeneca, Otsuka, and Novartis to validate the pivotal impact of your efforts
DELVING
into the series on “Optimizing Patient Engagement Measurements to Enhance Clinical Trial Outcomes”, guided by the expertise of Takeda and Black Diamond Therapeutics
FOSTERING
a measurement-centric culture internally and externally, incorporating perspectives from Ipsen Pharma, Alexion, Boehringer Ingelheim, and Cytokinetics
DEEPENING
your comprehension of the new FDA Patient-Focused Drug Development Guidance Series, with industry perspectives from Otsuka
ESTABLISHING
a shared baseline of metrics cross-functionally in collaboration with Novartis and Alkermes, seamlessly integrating shared terminology into your daily operations
CHARTING
a pragmatic course towards standardized metrics and reporting, drawing insights from AstraZeneca, Otsuka, and Novartis to validate the pivotal impact of your efforts
DELVING
into the series on “Optimizing Patient Engagement Measurements to Enhance Clinical Trial Outcomes”, guided by the expertise of Takeda and Black Diamond Therapeutics
FOSTERING
a measurement-centric culture internally and externally, incorporating perspectives from Ipsen Pharma, Alexion, Boehringer Ingelheim, and Cytokinetics
DEEPENING
your comprehension of the new FDA Patient-Focused Drug Development Guidance Series, with industry perspectives from Otsuka
ESTABLISHING
a shared baseline of metrics cross-functionally in collaboration with Novartis and Alkermes, seamlessly integrating shared terminology into your daily operations
Who Attended?
